Dynamic changes in intrinsic subtype, immunity status, and risk score before and after neoadjuvant chemo- and HER2-targeted therapy without pCR in HER2-positive breast cancers: A cross-sectional analysis

Very few studies have been done in HER2 positive patients without complete pathological response (pCR) after combined neoadjuvant chemo- and HER2-target therapy to investigate changes in intrinsic subtype, risk of recurrence (ROR) score, and immunity status before and after treatment. Patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Peixian, Mao, Xiaofan, Ma, Na, Wang, Chuan, Yao, Guangyu, Ye, Guolin, Zhou, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351872/
https://www.ncbi.nlm.nih.gov/pubmed/35945759
http://dx.doi.org/10.1097/MD.0000000000029877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351872/
https://www.ncbi.nlm.nih.gov/pubmed/35945759
http://dx.doi.org/10.1097/MD.0000000000029877

Ejemplares similares